WebFeb 23, 2024 · PAUL, Minn.--(BUSINESS WIRE)-- Cardiovascular Systems, Inc. (CSI ®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and ... Investor Relations & Corporate Communications (651) 202-4919 [email protected]. Source: … WebAug 3, 2024 · This document is intended to be read by investors in advance of regularly scheduled quarterly conference calls and was designed to provide a review of Glaukos Corporation’s recent financial and operational performance and general business outlook. Please see “Forward-Looking Statements” and “Statement Regarding Use of Non-GAAP …
Investors Landing - CSW Industrials
WebJan 13, 2024 · PAUL, Minn.-- (BUSINESS WIRE)-- Cardiovascular Systems, Inc. (CSI ®) (NASDAQ: CSII), a medical device company developing and commercializing innovative … WebJan 10, 2024 · Cardiovascular Systems, Inc. Common Stock (CSII) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. diabetic ketoacidosis early signs
GLAUKOS CORPORATION (NYSE: GKOS)
WebAug 2, 2024 · For the fiscal year ending Jun 2024 , the consensus EPS* forecast has remained the same over the past week at -0.67 and increased over the past month from -0.69 to -0.67 (2.90%). Of the 5 analysts ... WebQ2 FY22: U.S. Coronary 1 Is the total of Orbital Atherectomy System Revenue plus Interventional Support Device Revenue. 2 Includes coronary orbital atherectomy devices, Coronary ViperWire, ViperSlide and other 3 Includes Sapphire angioplasty balloons and Teleport microcatheters Modest Q/Q growth as COVID weighed on procedure volumes 5 … WebMar 28, 2024 · Investor Relations. Adrianne Griffin. T 214.489.7113 E [email protected]. Transfer Agent. AST. Brooklyn, New York T (800) 937-5449 www.amstock.com. Be a part of the team leading the industrial product market. Learn More. 5420 Lyndon B. Johnson Freeway diabetic ketoacidosis elevated glycosylated